Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
EHA 2024: Highlights in Multiple Myeloma
Joseph Mikhael, MD, discusses the latest trends and innovations regarding multiple myeloma management.
Joseph Mikhael, MD, discusses the PERSEUS trial findings presented at EHA 2024.
Dr. Mikhael discusses treatment in early relapse of multiple myeloma.
Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.
Dr. Mikhael outlines the significant hurdles in bispecific antibody therapy, as presented at the European Hematology Association's 2024 conference.
Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.
Advertisement
Advertisement
Trending on AJMC
1
Reduction in Food Allergies Found After Guideline-Directed Early Peanut Exposure
2
FDA Expands Semaglutide Label to Reduce Cardiovascular Risk in Adults With Type 2 Diabetes
3
Tezepelumab Becomes First TSLP-Targeting Biologic Approved by FDA for CRSwNP
4
Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis
5
